Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

Summary

This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.

Timeline

Start

2023-06-21

Primary completion

2027-10-01

Completion

2027-12-01

Drugs

Indications